JP2016185995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185995A5 JP2016185995A5 JP2016153074A JP2016153074A JP2016185995A5 JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5 JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- disease
- compound
- use according
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000003870 Drug Overdose Diseases 0.000 claims 2
- 102000003840 Opioid Receptors Human genes 0.000 claims 2
- 108090000137 Opioid Receptors Proteins 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 206010033296 Overdoses Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 231100000725 drug overdose Toxicity 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16170209P | 2009-03-19 | 2009-03-19 | |
| US61/161,702 | 2009-03-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046328A Division JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185995A JP2016185995A (ja) | 2016-10-27 |
| JP2016185995A5 true JP2016185995A5 (2) | 2016-12-28 |
| JP6362644B2 JP6362644B2 (ja) | 2018-07-25 |
Family
ID=42738186
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500776A Expired - Fee Related JP5555890B2 (ja) | 2009-03-19 | 2009-12-04 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014046328A Pending JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014097613A Withdrawn JP2014139257A (ja) | 2009-03-19 | 2014-05-09 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2016153074A Expired - Fee Related JP6362644B2 (ja) | 2009-03-19 | 2016-08-03 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500776A Expired - Fee Related JP5555890B2 (ja) | 2009-03-19 | 2009-12-04 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014046328A Pending JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014097613A Withdrawn JP2014139257A (ja) | 2009-03-19 | 2014-05-09 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20100240691A1 (2) |
| EP (2) | EP3170395A1 (2) |
| JP (4) | JP5555890B2 (2) |
| AU (1) | AU2009342654B2 (2) |
| CA (1) | CA2754984C (2) |
| WO (1) | WO2010107457A1 (2) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3170395A1 (en) * | 2009-03-19 | 2017-05-24 | Alkermes Pharma Ireland Limited | Morphinan derivatives with high oral bioavailability |
| TR201908514T4 (tr) * | 2009-12-04 | 2019-07-22 | Alkermes Pharma Ireland Ltd | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ |
| US8778960B2 (en) | 2010-08-23 | 2014-07-15 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
| US10195191B2 (en) | 2011-12-15 | 2019-02-05 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| AU2012351805B2 (en) * | 2011-12-15 | 2016-04-21 | Alkermes Pharma Ireland Limited | Samidorphan (ALKS 33) in combination with opioid agonists |
| LT3153171T (lt) * | 2011-12-15 | 2018-12-10 | Alkermes Pharma Ireland Limited | Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| ES2770978T3 (es) | 2013-05-24 | 2020-07-06 | Alkermes Pharma Ireland Ltd | Análogos de morfanos y morfinanos y métodos de uso |
| EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| JP2021531299A (ja) | 2018-07-23 | 2021-11-18 | トレビ セラピューティクス インコーポレイテッド | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
| KR20220127849A (ko) | 2020-01-10 | 2022-09-20 | 트레비 테라퓨틱스, 인코포레이티드 | 날부핀의 투여 방법 |
| US20230111856A1 (en) * | 2020-03-02 | 2023-04-13 | University Of Southern California | Opioid receptor antagonists |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| WO2025038406A1 (en) * | 2023-08-11 | 2025-02-20 | Virginia Commonwealth University | Design, synthesis, and biological evaluation of nitrogen-walk derivatives of nan as mu opioid receptor selective modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856795A (en) * | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
| US3957793A (en) * | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4032529A (en) * | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| US4127577A (en) * | 1975-11-24 | 1978-11-28 | Sterling Drug Inc. | Aminomethanobenzazocine process |
| US4205171A (en) * | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4649200A (en) * | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5258386A (en) * | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
| US5607941A (en) * | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| ATE229958T1 (de) * | 1996-01-10 | 2003-01-15 | Glaxosmithkline Spa | Heterocyclische kondensierte morphin-derivate |
| GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| AU2002227135B2 (en) * | 2000-10-31 | 2008-01-03 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| AU2005245403B2 (en) * | 2004-05-14 | 2012-04-19 | Janssen Pharmaceutica N.V. | Carboxamido opioid compounds |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| ES2387737T3 (es) * | 2004-11-05 | 2012-10-01 | Rensselaer Polytechnic Institute | 4-Hidroxibenzomorfanos |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089934A2 (en) * | 2006-02-01 | 2007-08-09 | Alkermes, Inc. | Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers |
| CN101827819B (zh) * | 2007-08-09 | 2013-06-12 | 伦斯勒理工学院 | 阿片样物质酰胺季铵盐 |
| EP3170395A1 (en) * | 2009-03-19 | 2017-05-24 | Alkermes Pharma Ireland Limited | Morphinan derivatives with high oral bioavailability |
| US20120149724A1 (en) * | 2009-06-04 | 2012-06-14 | The General Hospital Corporation | Modulating endogenous beta-endorphin levels |
| US9211293B2 (en) * | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| JP5929635B2 (ja) * | 2012-08-30 | 2016-06-08 | 株式会社デンソー | 多段式横型鍛造装置 |
-
2009
- 2009-12-04 EP EP16193161.3A patent/EP3170395A1/en not_active Withdrawn
- 2009-12-04 JP JP2012500776A patent/JP5555890B2/ja not_active Expired - Fee Related
- 2009-12-04 WO PCT/US2009/066801 patent/WO2010107457A1/en not_active Ceased
- 2009-12-04 CA CA2754984A patent/CA2754984C/en active Active
- 2009-12-04 EP EP09842019A patent/EP2408303A4/en not_active Withdrawn
- 2009-12-04 AU AU2009342654A patent/AU2009342654B2/en not_active Ceased
-
2010
- 2010-03-19 US US12/727,784 patent/US20100240691A1/en not_active Abandoned
-
2014
- 2014-03-10 JP JP2014046328A patent/JP2014101388A/ja active Pending
- 2014-05-09 JP JP2014097613A patent/JP2014139257A/ja not_active Withdrawn
- 2014-10-06 US US14/506,941 patent/US20150094325A1/en not_active Abandoned
-
2016
- 2016-08-03 JP JP2016153074A patent/JP6362644B2/ja not_active Expired - Fee Related
- 2016-11-17 US US15/354,244 patent/US20170112827A1/en not_active Abandoned
-
2020
- 2020-01-10 US US16/739,262 patent/US20200383970A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185995A5 (2) | ||
| JP2016106150A5 (2) | ||
| JP2012193216A5 (2) | ||
| JP2011068653A5 (2) | ||
| JP2012255026A5 (2) | ||
| JP2017506624A5 (2) | ||
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2013522212A5 (2) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2019517542A5 (2) | ||
| JP2014533272A5 (2) | ||
| JP2018513188A5 (2) | ||
| JP2016515628A5 (2) | ||
| JP2013541583A5 (2) | ||
| JP2019530706A5 (2) | ||
| JP2013516493A5 (2) | ||
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| JP2018531273A5 (2) | ||
| JP2012505830A5 (2) | ||
| JP2011500589A5 (2) | ||
| JP2016505050A5 (2) | ||
| JP2018506533A5 (2) | ||
| JP2017516842A5 (2) | ||
| JP2014520874A5 (2) | ||
| IL300144A (en) | Benzazepines are combined for the treatment of Tourette syndrome |